Vioxx and your heart

Researchers looked at 2,434 patients with stage 1 or stage 2 colorectal cancer, half of whom were taking 25 mg daily rofecoxib, sold under the brand name Vioxx.

The patients were taking Vioxx for an average of just 7.4 months before the trial was suddenly early, because of worldwide warnings about the increased heart risk from Vioxx.

An analysis of the trial found that of 23 heart & circulation problems that occurred during the study period, 16 happened while the patients were taking Vioxx or within two weeks of stopping treatment. This suggests an estimated risk for heart and circulation problems of 2.6 times greater for Vioxx over placebo.

Here's the full story:
http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20070725/vioxx_070725/20070725?hub=Health